ZA202304167B - Anti-cd47 antibodies and methods of use - Google Patents

Anti-cd47 antibodies and methods of use

Info

Publication number
ZA202304167B
ZA202304167B ZA2023/04167A ZA202304167A ZA202304167B ZA 202304167 B ZA202304167 B ZA 202304167B ZA 2023/04167 A ZA2023/04167 A ZA 2023/04167A ZA 202304167 A ZA202304167 A ZA 202304167A ZA 202304167 B ZA202304167 B ZA 202304167B
Authority
ZA
South Africa
Prior art keywords
antibodies
methods
antibody
mer6
iap
Prior art date
Application number
ZA2023/04167A
Other languages
English (en)
Inventor
Jiin-Tarng Wang
Chi-Ling Tseng
Wei-Dong Jiang
Original Assignee
Shanghai Henlius Biotech Inc
Shanghai Henlius Biopharmaceutical Co Ltd
Shanghai Henlius Biologics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Henlius Biotech Inc, Shanghai Henlius Biopharmaceutical Co Ltd, Shanghai Henlius Biologics Co Ltd filed Critical Shanghai Henlius Biotech Inc
Publication of ZA202304167B publication Critical patent/ZA202304167B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA2023/04167A 2020-09-28 2023-04-05 Anti-cd47 antibodies and methods of use ZA202304167B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020118320 2020-09-28
PCT/CN2021/121314 WO2022063316A1 (en) 2020-09-28 2021-09-28 Anti-cd47 antibodies and methods of use

Publications (1)

Publication Number Publication Date
ZA202304167B true ZA202304167B (en) 2023-10-25

Family

ID=80844512

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/04167A ZA202304167B (en) 2020-09-28 2023-04-05 Anti-cd47 antibodies and methods of use

Country Status (9)

Country Link
US (1) US20230279110A1 (https=)
EP (1) EP4217397A4 (https=)
JP (1) JP7820364B2 (https=)
KR (1) KR20230079393A (https=)
CN (1) CN116323675A (https=)
AU (1) AU2021346729A1 (https=)
CA (1) CA3191835A1 (https=)
WO (1) WO2022063316A1 (https=)
ZA (1) ZA202304167B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102757518B1 (ko) * 2020-12-07 2025-01-21 (주)이노베이션바이오 Cd47에 특이적인 항체 및 이의 용도
KR20250172692A (ko) 2021-12-21 2025-12-09 에프비디 바이올로직스 리미티드 조작된 SIRPα 변이체 및 이의 사용 방법
WO2024140998A2 (en) * 2022-12-29 2024-07-04 Shanghai Henlius Biotech, Inc. Anti-pdl1 antibodies, multispecific antibodies and methods of use
IL321674A (en) * 2022-12-29 2025-08-01 Shanghai Henlius Biotech Inc Anti-cd47 antibodies and methods of use
EP4490201A4 (en) 2023-05-31 2026-03-11 Fbd Biologics Ltd CD47/PD-L1 Targeted Protein Complex and Its Methods of Use
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190112374A1 (en) * 2010-05-14 2019-04-18 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
PT3402820T (pt) 2016-01-11 2020-08-20 Forty Seven Inc Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados
EP3454900A4 (en) * 2016-05-09 2020-01-29 Celgene Corporation CD47 ANTIBODIES AND METHODS OF USE
CN106117354B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗CD47的全分子IgG抗体及其应用
EP3532497B1 (en) 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
EA039662B1 (ru) * 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
CA3089512A1 (en) * 2018-01-24 2019-08-01 Nanjing Legend Biotech Co., Ltd. Anti-cd47 antibodies that do not cause significant red blood cell agglutination
CN111087470B (zh) * 2020-01-19 2022-05-10 中国人民解放军第四军医大学 一种抗人CD47单克隆抗体7G4mAb及其应用

Also Published As

Publication number Publication date
US20230279110A1 (en) 2023-09-07
KR20230079393A (ko) 2023-06-07
WO2022063316A1 (en) 2022-03-31
EP4217397A4 (en) 2025-01-08
EP4217397A1 (en) 2023-08-02
JP2023544294A (ja) 2023-10-23
CN116323675A (zh) 2023-06-23
AU2021346729A1 (en) 2023-05-11
JP7820364B2 (ja) 2026-02-25
CA3191835A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
ZA202304167B (en) Anti-cd47 antibodies and methods of use
WO2021163064A3 (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
WO2006121422A3 (en) Antibodies against clostridium difficile toxins and uses thereof
NZ767596A (en) Antibodies that bind cd39 and uses thereof
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
EP4681726A3 (en) Anti-par2 antibodies and uses thereof
WO2008140493A3 (en) Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
AU2011343161A8 (en) Human anti-SOD1 antibodies
EP4108684A4 (en) ANTIBODY BINDING TO TIGIT ANTIGEN, PREPARATION METHOD AND USE THEREOF
WO2008150485A3 (en) Erbb2 binding proteins and use thereof
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
WO2009048839A3 (en) Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
NZ602220A (en) Antibodies with ph dependent antigen binding
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
WO2020172621A8 (en) Cd33 antibodies and methods of using the same to treat cancer
WO2007116360A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2009055074A8 (en) Erbb2 binding proteins and use thereof
WO2018183182A8 (en) Methods and compositions for reduction of immunogenicity
SG156668A1 (en) Angiopoietin-2 specific binding agents
EP4670724A3 (en) Anti-gprc5d monoclonal antibodies and uses thereof
EP4110826A4 (en) ANTI-CD137 CONSTRUCTS, MULTI-SPECIFIC ANTIBODY AND ITS USES
MX2025002569A (es) Anticuerpos anti-trop2/egfr y usos de estos
EP4087877A4 (en) ANTI-TIGITE ANTIBODIES, MULTI-SPECIFIC ANTIBODIES CONTAINING SAME AND METHOD FOR USE THEREOF
WO2021207948A9 (en) Anti-sars-cov-2 antibodies and uses thereof
WO2022204713A3 (en) Antibodies to sars-cov-2